|
|
| | 1,2-Dithiolane-3-pentanamide, N-[4-(5-isoquinolinylamino)cyclohexyl]- Basic information |
| | 1,2-Dithiolane-3-pentanamide, N-[4-(5-isoquinolinylamino)cyclohexyl]- Chemical Properties |
| Boiling point | 679.7±50.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | pka | 15.86±0.40(Predicted) |
| | 1,2-Dithiolane-3-pentanamide, N-[4-(5-isoquinolinylamino)cyclohexyl]- Usage And Synthesis |
| Uses | PT109 is a multi-kinase inhibitor. PT109 inhibits JNK (JNK1: IC50=0.143 μM; JNK2: IC50=0.831 μM; JNK3: IC50=0.285 μM) and other kinases (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM; ROCK2: IC50=34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity[1][2]. | | IC 50 | JNK1: 0.143 μM (IC50); JNK2: 0.831 μM (IC50); JNK3: 0.285 μM (IC50); SGK1: 1.34 μM (IC50); SGK3: 26.4 μM (IC50); ROCK2: 34 μM (IC50) | | References | [1] Chen Q, et al. Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo[J]. European Journal of Pharmacology, 2020, 883: 173361. DOI:10.1016/j.ejphar.2020.173361 [2] Yang Y, et al. PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway[J]. European Journal of Pharmacology, 2022, 920: 174837. DOI:10.1016/j.ejphar.2022.174837 |
| | 1,2-Dithiolane-3-pentanamide, N-[4-(5-isoquinolinylamino)cyclohexyl]- Preparation Products And Raw materials |
|